Why Attend
The Onco Cell Therapy Summit (OCTS) is the only industry-led meeting covering the full range of autologous and allogeneic cell product advancements. A four-tracked agenda, featuring pioneering biopharma, academia, and solution-providers, will address all innovative MoA, manufacturing challenges, and clinical progress of CAR T, TCR T, TILs, Macrophages, and NK cells in treating haematological and solid tumors. Expect to hear from CXOs, VPs, R&D and Process Developers on the opportunities generated from recent clinical and technological data, and how they are tackling the most pressing industry challenges to get effective treatments to patients.
To facilitate connections between relevant peers and spark solution-led discussions, the summit is broken down into four streamlined tracks – Pre-clinical & Translational Research, Clinical, Manufacturing and Logistics & Market Access. You will be able to step into interactive discussions and engaging presentations on the key product development questions:
1. How to expand the durability of response by targeting antigen heterogeneity, optimized affinity, specificity and reduce cell exhaustion in the TME?
2. How can genome editing technologies lead to successful clinical applications?
3. What clinical progress is being made in 'off-the-shelf' allogeneic cell therapies?
4. How to make the transition from proven research-scale to production-scale through a robust manufacturing platform?
5. Where to direct resources to build resilience and create a ‘vein-to-vein’ and IPSC-derived, patient-centric cell therapy supply chain?
OCTS will enable your teams to identify the rationale and progress in developing cell engineering platforms to generate a robust pipeline of potent, safe therapies. There will be a 360-view of the ongoing phase 1 / 2 trials, building out cGMP manufacturing capabilities through automation and in-process analytics, recalibrating supply chains to build resilience in a dynamic research field and ensuring novel therapies address unmet clinical need.
WHO WILL BE THERE
Network with industry experts from:
- Senior-level leaders from biotech and representatives from big pharma
- Academic experts in cell therapy
- Process standardisation - technology/services
- Logistics companies - cell storage/transport
- Service providers – CROs, CDMOs, consultants, logistics companies and more
Last year's attendees included:
Confirmed 2022 Speakers
John Langowski
Peter Bross
Crystal L Mackall MD
Ernest and Amelia Gallo Family Professor of Pediatrics and Medicine
Director, Stanford Center for Cancer Cell Therapy
Director, Parker Institute for Cancer Immunotherapy at Stanford
Co-Executive Director, Stanford Laboratory for Cell and Gene Medicine
Associate Director, Stanford Cancer Institute
Arun Balakumaran
Vered Caplan
Birgit Schultes
Snehal Patel
Snehal Patel is the Global Head and Vice President for Cell Therapy Manufacturing for Bristol Myers Squibb (BMS). He leads the growing global manufacturing network to produce Clinical and Commercial Cell Therapy Products, including the two cell therapies recently launched in 2021 by BMS. Overseeing three state-of-the-art production facilities, Snehal is also closely involved in planning, development and construction of two additional facilities to continue expanding BMS’ global footprint. In addition, he has served as Site Head for Cell Therapy Manufacturing and is based in Seattle, WA. He started at BMS via the Juno Therapeutics acquisition in February 2018.
Prior to joining BMS, Snehal worked at Genentech/Roche for ~18 years, holding a variety of different roles with increasing responsibility, including Head of Global External Drug Product Manufacturing, Head of Drug Product Operations, and Head of Quality Operations.
Snehal has a breadth of knowledge and experience including leadership roles in Technical Operations, Technology, Training, and Quality Assurance in Biologics, Small Molecules, and Cell Therapy. He is routinely sought out for his technical expertise, as well as his ability to collaborate and influence. He is a dynamic leader where he focuses on Inspirational Leadership and Development of his team.
Serena De Vita
Debora Barton, MD
Kate Rochlin
Christopher Pastorello
Robbie Majzner
Eric Halioua
Cheng Liu
Carnley Norman
Austin Boesch
Christian Hinrichs
Stefanie Bailey
Michael Leek
Paul Rennert
Guanglin Yu
Adham Bear
Moonsoo Jin
Mark Yarmarkovich
Jorge Mansilla-Soto
John Lu
Branden Moriarity
Jan ter Meulen
Gavin MacBeath
Alba Gonzalez
Amanda Conerty
David Brochu
Jeffrey S Miller
Jennifer Buell
Lucas de Breed
Matthew Li
Gail Turner
Melissa Sebok
Reagan Jarvis
Markus Gruell
Robert Tighe
Christina Bailey
Laura Johnson
Steven Doares
Pete Smith
Breanna DiAndreth
Subhadra Jayaraman
Lucia Poncette
Lucia is T-knife‘s Director TCR discovery and is one of its founding scientists. She studied Human Biology in Marburg and Toowoomba (Australia) and obtained a doctor’s degree in tumor immunology from the Free University of Berlin followed by a PostDoc at the Max Delbrück Center for Molecular Medicine in Berlin. For the last 10 years Lucia has studied T cell receptors and their application in the treatment of cancer. At T-knife Lucia oversees the early development and characterization of T cell receptors using T-knife‘s proprietary myT platform.
Stefania Gobessi
Raymond Luke
Vineet Kacker
Ashish Kothari
Nissim Darvish
David Moskowitz
Ansbert Gadicke
Philip Lee
Jennifer McDevitt
David Ferrick
Brian Newsom
Jens Eberlein
Get The Agenda
What's New For 2022?
- Dedicated ‘Preclinical and Translational Science’ track focused on ‘Developing Versatile Cell Therapy Engineering Platforms, with specific talks on targeting antigen heterogeneity (Talks from A2 Biotherapeutics, T-Knife Therapeutics, Enara Bio, Eureka Therapeutics), improving cell therapy durability (Talks from Aleta Biotherapeutics, TCR2 Therapeutics), harnessing innate immune cells (Talks from Senti Bio, Caribou Biosciences).
- Specific talks and discussion on gene modification strategies for next-generation cell therapy products (Talks from Intellia Therapeutics, Allogene Therapeutics, Mammoth Biosciences, In8bio).
- What clinical progress is being made in 'off-the-shelf' allogeneic cell therapies (Talks from Rutgers Cancer Institute of New Jersey, MiNK Therapeutics, PDC*Line Pharma).
- Focused track on developing manufacturing capabilities on a clinical scale and scaling into the commercial setting (Talks from TC Biopharm, Century Therapeutics, Bristol Myers Squibb, Kite Pharma).
- As more biotechs look beyond clinical development and plan for future market access strategies, OCTS 2022 now has dedicated sessions addressing this subject (Talks from Bayer Pharmaceuticals, Instil Bio, August Care).
Download The 2022 Agenda
Partners
Platinum Partner
Miltenyi Biotec
Website: https://www.miltenyibiotec.com/GB-en/
Please visit our website for more information.Lonza
Website: https://www.lonza.com/
At Lonza, we combine technological innovation with world class manufacturing and process excellence. Together, these enable our customers to deliver their discoveries in the healthcare, preservation, and protection sectors.
We are a preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to prevent illness and promote a healthier world by enabling our customers to deliver innovative medicines that help treat or even cure a wide range of diseases. We also offer a broad range of microbial control solutions, which help to create and maintain a healthy environment. We focus on enabling treatments that prevent illness, support healthier lifestyles and create a healthy environment. We optimize scientific innovation and manufacturing technology to enable our customers to serve their patients and consumers.
Founded in 1897 in the Swiss Alps, Lonza today operates in 120 sites and offices in more than 35 countries. With approximately 16,000 full-time employees, we are built from high-performing teams and of individual employees who make a meaningful difference to our own business, as well as the communities in which we operate. The company generated sales of CHF 5.4 billion in 2021 with a CORE EBITDA of CHF 1.7 billion.
Find out more at www.lonza.com and follow us on Twitter @LonzaGroup or Facebook @LonzaGroupAG.
Gold Partners
American Red Cross
Website: RedCrossBlood.org/cellulartherapy
The Cell & Gene Therapy Solutions division of the American Red Cross is a nationwide leader in the provision of allogeneic and autologous collections for cell and gene therapy. Our products support a broad range of uses, from bench research to use in clinical trials and the manufacture of commercial therapies.
We currently perform autologous Mononuclear Cell collections at 62 Red Cross sites across the country and at multiple hospital locations. Our allogeneic Mononuclear Cell products are collected from healthy donors at five Red Cross sites across the country, and can be shipped fresh or frozen.
Our five full-service cellular therapy labs perform processing, freezing and storage of apheresis material. This, along with our ability to offer robust customization, allows us to both collect and process apheresis products according to our customers’ specifications and unique needs.
Apcer LS
Website: https://www.apcerls.com/
APCER Life Sciences provides comprehensive drug safety/pharmacovigilance, medical information, medical writing, regulatory services, quality assurance and risk management programs to pharmaceutical and biotech companies globally.
Advanced Therapy Medicinal Product (ATMP) companies need to take a long-term approach towards collection and analysis of safety data for maintaining the overall risk-benefit balance and address challenges like long-term follow-ups, potential autoimmune reaction risks, and complex causality assessments arising out of long latent period between therapy and associated side effects.
Our scientific expertise, focus on Patient Safety & Risk Profile Management approach makes us the preferred pharmacovigilance services partner for ATMP companies throughout the lifecycle management.
LUMICKS
Website: https://lumicks.com/
LUMICKS creates instruments for dynamic single-molecule and cell avidity analysis. Our flagship instrument for Immuno-oncology, the z-Movi® Cell Avidity Analyzer, enables the measurement and selection of immune cells based on their interactions with cancer cells, providing a new functional biomarker for experimentally evaluating immune cell functionality and activation. With this technology, scientists can measure cell avidity and obtain predictive, reproducible, and fast results to compare several types of immunotherapeutic strategies, including CAR T cells, TCR engineered T cells, cell engagers, and CAR-NK / NK cells.
ScaleReady
ScaleReady is a joint venture between Bio-Techne, Fresenius Kabi, and Wilson Wolf. Bringing together proven tools and technologies for cell culture, cell activation, gene editing, and cell processing, ScaleReady provides leading therapeutic developers with the most simple, scalable, and versatile manufacturing platform in the industry. Our platform includes G-Rex® cell culture technology, the Lovo and Cue cell processing systems, and a wide range of GMP proteins, reagents, media, and gene editing technologies.
Terumo
Website: https://www.terumobct.com/cell-therapy-technologies
Cell and gene therapy developers work with Terumo Blood and Cell Technologies when they want more than just our portfolio of automated devices. Not only do we enable unparalleled excellence in cell collections, but we also bring the expertise in automating and closing the manufacturing process of biological products. Our team of experts are dedicated to working alongside customers to help them achieve their goals from early-stage development to commercialization.
Event Partners
Axion BioSystems
Website: https://www.axionbiosystems.com
Please visit our website for more information.
Barrington James
Website: https://barringtonjames.com/
Please visit our website for more information.Fenix - Cellteligence
Website: https://celltelligence.com/
Please visit our website for more information.Lonza
Website: https://www.lonza.com/
At Lonza, we combine technological innovation with world class manufacturing and process excellence. Together, these enable our customers to deliver their discoveries in the healthcare, preservation, and protection sectors.
We are a preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to prevent illness and promote a healthier world by enabling our customers to deliver innovative medicines that help treat or even cure a wide range of diseases. We also offer a broad range of microbial control solutions, which help to create and maintain a healthy environment. We focus on enabling treatments that prevent illness, support healthier lifestyles and create a healthy environment. We optimize scientific innovation and manufacturing technology to enable our customers to serve their patients and consumers.
Founded in 1897 in the Swiss Alps, Lonza today operates in 120 sites and offices in more than 35 countries. With approximately 16,000 full-time employees, we are built from high-performing teams and of individual employees who make a meaningful difference to our own business, as well as the communities in which we operate. The company generated sales of CHF 5.4 billion in 2021 with a CORE EBITDA of CHF 1.7 billion.
Find out more at www.lonza.com and follow us on Twitter @LonzaGroup or Facebook @LonzaGroupAG.
Exhibitors
American Red Cross
Website: RedCrossBlood.org/cellulartherapy
The Cell & Gene Therapy Solutions division of the American Red Cross is a nationwide leader in the provision of allogeneic and autologous collections for cell and gene therapy. Our products support a broad range of uses, from bench research to use in clinical trials and the manufacture of commercial therapies.
We currently perform autologous Mononuclear Cell collections at 62 Red Cross sites across the country and at multiple hospital locations. Our allogeneic Mononuclear Cell products are collected from healthy donors at five Red Cross sites across the country, and can be shipped fresh or frozen.
Our five full-service cellular therapy labs perform processing, freezing and storage of apheresis material. This, along with our ability to offer robust customization, allows us to both collect and process apheresis products according to our customers’ specifications and unique needs.
Apcer LS
Website: https://www.apcerls.com/
APCER Life Sciences provides comprehensive drug safety/pharmacovigilance, medical information, medical writing, regulatory services, quality assurance and risk management programs to pharmaceutical and biotech companies globally.
Advanced Therapy Medicinal Product (ATMP) companies need to take a long-term approach towards collection and analysis of safety data for maintaining the overall risk-benefit balance and address challenges like long-term follow-ups, potential autoimmune reaction risks, and complex causality assessments arising out of long latent period between therapy and associated side effects.
Our scientific expertise, focus on Patient Safety & Risk Profile Management approach makes us the preferred pharmacovigilance services partner for ATMP companies throughout the lifecycle management.
Axion BioSystems
Website: https://www.axionbiosystems.com/
Please visit our website for more information.Barrington James
Website: https://barringtonjames.com/
Please visit our website for more information.CellGenix (part of Sartorius group)
Website: https://cellgenix.com/
Sartorius CellGenix is a leading global supplier of high quality raw materials for the expanding cell and gene therapy market. We develop, manufacture and market preclinical and GMP cytokines along with GMP serum-free media for further manufacturing of ATMPs. Our products are used by academia and industry partners in preclinical development, clinical trials, and commercial manufacturing throughout the world.
With +25 years of experience, we are experts in the GMP manufacturing of raw materials for the cell and gene therapy space. By offering expert technical and regulatory support we can help simplify raw material qualification and validation efforts.
Cellply
Website: https://cellply.com/
Cellply delivers a unique platform for in depth single-cell functional and potency characterization from complex heterogeneous immune cell populations using Coculture arrayTM technology. The walkaway, fully automated platform delivers high throughput analysis of serial killing measurements along with cytotoxicity, cytokine release and other assays. Each measurement can be generated in relation to the subpopulations of immune cells based on immunophenotype, or as a bulk measurement. The walkaway automation, hands off utility and multi-assay capability make it a perfect tool for R&D through release testing via rapid identification of the best candidates while using minimal labor and time to achieve results.
Lonza
Website: https://www.lonza.com/
At Lonza, we combine technological innovation with world class manufacturing and process excellence. Together, these enable our customers to deliver their discoveries in the healthcare, preservation, and protection sectors.
We are a preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to prevent illness and promote a healthier world by enabling our customers to deliver innovative medicines that help treat or even cure a wide range of diseases. We also offer a broad range of microbial control solutions, which help to create and maintain a healthy environment. We focus on enabling treatments that prevent illness, support healthier lifestyles and create a healthy environment. We optimize scientific innovation and manufacturing technology to enable our customers to serve their patients and consumers.
Founded in 1897 in the Swiss Alps, Lonza today operates in 120 sites and offices in more than 35 countries. With approximately 16,000 full-time employees, we are built from high-performing teams and of individual employees who make a meaningful difference to our own business, as well as the communities in which we operate. The company generated sales of CHF 5.4 billion in 2021 with a CORE EBITDA of CHF 1.7 billion.
Find out more at www.lonza.com and follow us on Twitter @LonzaGroup or Facebook @LonzaGroupAG.
LUMICKS
Website: https://lumicks.com/
LUMICKS creates instruments for dynamic single-molecule and cell avidity analysis. Our flagship instrument for Immuno-oncology, the z-Movi® Cell Avidity Analyzer, enables the measurement and selection of immune cells based on their interactions with cancer cells, providing a new functional biomarker for experimentally evaluating immune cell functionality and activation. With this technology, scientists can measure cell avidity and obtain predictive, reproducible, and fast results to compare several types of immunotherapeutic strategies, including CAR T cells, TCR engineered T cells, cell engagers, and CAR-NK / NK cells.
Luminary Therapeutics
Website: https://www.luminarytx.com
Please visit our website for more information.Miltenyi Biotec
Website: https://www.miltenyibiotec.com/GB-en/
Please visit our website for more information.Noble Life Sciences
Website: https://noblelifesci.com/
Noble Life Sciences is a preclinical CRO providing in vitro and in vivo testing services for cell and gene therapy, biologics, vaccines, drugs, and devices.
Services include animal models, pharmacology, early safety assessments, toxicology, GLP custom polyclonal antibodies, and analytical testing.
QuickSTAT Global Life Sciences
Website: https://quickstat.quick.aero/
Please visit our website for more information.ScaleReady
ScaleReady is a joint venture between Bio-Techne, Fresenius Kabi, and Wilson Wolf. Bringing together proven tools and technologies for cell culture, cell activation, gene editing, and cell processing, ScaleReady provides leading therapeutic developers with the most simple, scalable, and versatile manufacturing platform in the industry. Our platform includes G-Rex® cell culture technology, the Lovo and Cue cell processing systems, and a wide range of GMP proteins, reagents, media, and gene editing technologies.
Terumo
Website: https://www.terumobct.com/cell-therapy-technologies
Cell and gene therapy developers work with Terumo Blood and Cell Technologies when they want more than just our portfolio of automated devices. Not only do we enable unparalleled excellence in cell collections, but we also bring the expertise in automating and closing the manufacturing process of biological products. Our team of experts are dedicated to working alongside customers to help them achieve their goals from early-stage development to commercialization.
Media Partners
FreeMind
Website: https://www.freemindconsultants.com/
FreeMind Group helps life science companies win non-dilutive funds from US federal agencies and private foundations to fund their R&D. We maximize potential to receive grants and contracts from the NIH, DOD, CDMRP, NSF, FDA, BARDA, etc., as well as private foundations.
Established in 1999, FreeMind is the largest consulting group of its kind, working with companies and academic researchers around the world. Our long-term strategic approach has garnered our clients over $1.7 billion to date. Awards range from $150,000 to $150,000,000 per project, and our team of experts helps make non-dilutive funding a key tool in a sound, long-term financial strategy.
Gene Therapy Net
Website: https://www.genetherapylive.com/
Gene Therapy Net is the information resource for basic and clinical research in gene therapy, and the site serves as a network for the exchange of gene therapy information and breaking news items. Visitors can keep track of the latest scientific papers, conference announcements, gene therapy jobs, regulations and guidelines.
Pharma Advancement
Website: https://www.pharmaadvancement.com/advertise-with-us/
Please visit our website for more information.Pharma Journalist
Website: http://www.pharmajournalist.com
Please visit our website for more information.STEMCELL Science News
Website: https://bit.ly/3B39dia
Looking to stay up to date on the latest cell biology research? Science News by STEMCELL Technologies can help. Our website and weekly newsletters keep scientists current with the latest peer-reviewed research, as well as industry and policy news.
World Pharma Today
Website: https://www.worldpharmatoday.com/
Please visit our website for more information.Non-Profit Partner
Alliance for Cancer Gene Therapy
Website: https://acgtfoundation.org/groundbreaking-research/what-were-working-on/
Please join the Alliance for Cancer Gene Therapy in turning transformative ideas into life-saving therapies. For 20 years, we have backed innovative scientists in creating pioneering treatments with life-saving results.
ACGT is the only public charity dedicated exclusively to cancer cell and gene therapy research. 100% of all public donations go directly to researchers, vetted and chosen by ACGT’s esteemed Scientific Advisory Council.
https://acgtfoundation.org/donate/
PARTNER WITH US
Based on your objectives, we can create bespoke packages designed specifically for you. From presenting your expertize on the main stage to hosting the infamous CAR-T Party. You can partner with us showcase your brand and make valuable new connections. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding & Networking.
Take a look at the Sponsorship Prospectus for more details, or discuss your objectives with Ryan Sanderson, Commercial Partnerships Director; [email protected].
DOWNLOAD THE SPONSORSHIP PROSPECTUS HERE.
Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact Laura Hobson, Senior Marketing Manager; [email protected]
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 5% Off
Book a Team of 5+ - Save an Additional 10% Off
Book a Team of 10+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
Terms & Conditions
In the event that Kisaco Research postpones an event for any reason or changes the event format to ‘virtual event’, any in-person registrations for this event will be automatically transferred to the virtual registration package. The delegate will receive a credit note for the difference in ticket value from the fee paid. You may use this credit for another Kisaco Research event to be mutually agreed with Kisaco Research, which must occur within 12 months from the date of the event which the delegate had originally registered for.
OCTS Innovation Awards 2022
The OCTS Innovation Awards, part of the Onco Cell Therapy Summit in Boston (June 29-30), are a fantastic opportunity to recognise leaders and pioneers who have been instrumental to innovation in an incredibly exciting year for the cell therapy industry.
The awards are a people’s choice vote for excellence in cell therapy. We will open up nominations and voting to a universal network of industry leaders.
If you, or someone you know, has spearheaded innovation in cell therapy, or has been pivotal in the implementation of in-house innovation, we want to celebrate your achievements and empower you for future success!
CATEGORIES FOR 2022:
Solution Provider of the Year
For organisations who have demonstrated passion, skill, and expertise in developing a world class solution/service in cell and gene therapy.
Biotech Innovator of the Year
Celebrating the outstanding contribution of an individual who is driving meaningful change or spearheading innovative projects.
Venue
Hynes Convention Center
900 Boylston St, Boston, MA 02115, United States
To view local hotels near to the event venue please click here: https://hotelmap.com/hotels/MLSLZ
Returning Safely Measures
Whether sponsors, speakers or attendees, our customers attend Kisaco Research events to connect, learn and innovate to know more and do business. It is our commitment that as we return to in-person events, they can do this effectively, safely and with confidence.
All in-person Kisaco Research events will prioritize the health and safety of colleagues and customers and, in the first instance, will be run in accordance with official government and local authority guidance, as well as any venue or location-specific regulations.
Kisaco Research is committed to following the Association of Event Organisers All Secure Standard, which has been approved by by UK Government.
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.